PMGC HOLDINGS INC (ELAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.65-14.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ELAB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
NorthStrive Defense Tech has been established to serve as a focused platform for the Company’s strategy to identify, acquire, and license advanced defense technologies, with an initial emphasis on dr…
Stated in 1 of 2 supplied quarters. Management reported: “NorthStrive Defense Tech has been established to serve as a focused platform for the Company’s strategy to identify, acquire, and license advanced defense technologies, with an initial emphasis on drone and autonomous systems.” “The formation of NorthStrive Defense Tech reflects PMGC’s continued expansion into sectors it views as high growth.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“NorthStrive Defense Tech has been established to serve as a focused platform for the Company’s strategy to identify, acquire, and license advanced defense technologies, with an initial emphasis on dr…”
The Amendment formalizes the launch of a three-phase Expansion Program to advance all four AI-discovered compounds toward lead compound nomination and updates key terms of the underlying agreement, i…
Stated in a supplied disclosure. Management reported: “The Amendment formalizes the launch of a three-phase Expansion Program to advance all four AI-discovered compounds toward lead compound nomination and updates key terms of the underlying agreement, including AI Development Program scope, the IP framework, governing developed technology, the field of use definitions, and associated financial terms.” “The program is expected to take approximately 6 months and will culminate in the nomination of a lead compound and designated backup for further development.”
Based on these findings, NorthStrive plans to design a follow-on preclinical study evaluating EL-32 in combination with a lower dose of semaglutide, with lean mass and body composition considered to…
Stated in a supplied disclosure. Management reported: “Based on these findings, NorthStrive plans to design a follow-on preclinical study evaluating EL-32 in combination with a lower dose of semaglutide, with lean mass and body composition considered to be the primary endpoints, and expects to provide an update on the design and timing of that study in the first quarter of 2027.” “The results will also inform NorthStrive’s broader EL-22 and EL-32 development program, including the analytical characterization work with Charles River Laboratories announced on September 29, 2026 and the planned spaceflight study under the Orbit2Orbit term sheet announced on August 25, 2026.”
The stub period financial statements have been prepared in connection with a potential sale transaction.
4 A&B AEROSPACE, INC. Notes to the Financial Statements (unaudited) Notes to the Financial Statements As of February 28, 2026 and May 31, 2025, and for the three and nine months ended February 28, 20…
Over the trailing year it converted 0.82x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
51 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.